(VIANEWS) – The NASDAQ opens in less than three hours and TherapeuticsMD‘s pre-market value is already 8.79% up.
TherapeuticsMD’s last close was $4.21, 89.06% below its 52-week high of $38.50.
The last session, NASDAQ finished with TherapeuticsMD (TXMD) falling 5.39% to $4.21. NASDAQ jumped 0.99% to $11,285.32, after two successive sessions in a row of gains, on what was a somewhat up trend exchanging session.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.
TherapeuticsMD’s sales growth is 8.6% for the ongoing quarter and 3.6% for the next.
More news about TherapeuticsMD (TXMD).